This website uses cookies that help the website function and that help us understand how you interact with it. Please read our privacy policy for more information.
This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.